Synthesis of tenascin and laminin beta2 chain in human bronchial epithelial cells is enhanced by cysteinyl leukotrienes via CysLT1 receptor by Altraja, Siiri et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
Respiratory Research
Open Access Research
Synthesis of tenascin and laminin beta2 chain in human bronchial 
epithelial cells is enhanced by cysteinyl leukotrienes via CysLT1 
receptor
Siiri Altraja1,2, Martin Kadai3, Erki Rekker4 and Alan Altraja*4
Address: 1Institute of General & Molecular Pathology, University of Tartu, Tartu, Estonia, 2Estonian Biocentre, Tartu, Estonia, 3Institute of 
Molecular & Cell Biology, University of Tartu, Tartu, Estonia and 4Department of Pulmonary Medicine, University of Tartu, Tartu, Estonia
Email: Siiri Altraja - siiri.altraja@ut.ee; Martin Kadai - kada@ut.ee; Erki Rekker - erx@ut.ee; Alan Altraja* - alan@kliinikum.ee
* Corresponding author    
Abstract
Background: Cysteinyl leukotrienes (CysLTs) are key mediators of asthma, but their role in the
genesis of airway remodeling is insufficiently understood. Recent evidence suggests that increased
expression of tenascin (Tn) and laminin (Ln) β2 chain is indicative of the remodeling activity in
asthma, but represents also an example of deposition of extracellular matrix, which affects the
airway wall compliance. We tested the hypothesis that CysLTs affect production of Tn and Ln β2
chain by human bronchial epithelial cells and elucidated, which of the CysLT receptors, CysLT1 or
CysLT2, mediate this effect.
Methods: Cultured BEAS-2B human bronchial epithelial cells were stimulated with leukotriene D4
(LTD4) and E4 (LTE4) and evaluated by immunocytochemistry, Western blotting, flow cytometry,
and RT-PCR. CysLT receptors were differentially blocked with use of montelukast or BAY u9773.
Results: LTD4 and LTE4 significantly augmented the expression of Tn, whereas LTD4, distinctly
from LTE4, was able to increase also the Ln β2 chain. Although the expression of CysLT2 prevailed
over that of CysLT1, the up-regulation of Tn and Ln β2 chain by CysLTs was completely blocked
by the CysLT1-selective antagonist montelukast with no difference between montelukast and the
dual antagonist BAY u9773 for the inhibitory capacity.
Conclusion: These findings suggest that the CysLT-induced up-regulation of Tn and Ln β2 chain,
an important epithelium-linked aspect of airway remodeling, is mediated predominantly by the
CysLT1 receptor. The results provide a novel aspect to support the use of CysLT1 receptor
antagonists in the anti-remodeling treatment of asthma.
Background
Airway remodeling is a fundamental abnormality in the
pathobiology of inflammatory airway diseases like bron-
chial asthma and chronic obstructive pulmonary disease
(COPD) [1,2]. This remodeling is irreversible in its many
aspects including airway fibrosis and deposition of new
extracellular matrix (ECM) components into the airway
wall [2]. These events lead to a thickened airway wall with
markedly reduced airway caliber resulting in progressive
development of fixed airflow limitation [2-4]. In asthmat-
ics, increased deposition of collagen types I and III, but
also tenascin (Tn) and laminin (Ln) chains α2 and β2
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beneath the airway epithelium have been described [5-7],
whereas the subepithelial Tn deposition is severity-
dependent and can be reduced by anti-inflammatory
treatment [7]. In bronchial epithelial cells in vitro, Tn can
be up-regulated by cytokines like transforming growth
factor-β (TGF-β) [8] and tumor necrosis factor-α (TNF-α)
[9], which are also operative in asthma. Judged by rapid
turnover of Tn in the bronchial mucosa [10], the up-regu-
lation of Tn in asthma may refer to its role in inflamma-
tion and immediate repair. However, in addition to
serving as a marker of ongoing inflammation, the deposi-
tion of Tn can contribute to increased airway narrowing
and decreased airway wall compliance, as does the depo-
sition of other ECM components.
Experimental data suggest that cysteinyl leukotrienes
(CysLTs), known mainly as effector mediators in asthma,
induce a broad spectrum of pathophysiological responses
[11]. CysLTs contribute to airway remodeling not only
through their diverse roles in inflammation, but also by
their direct effects on lung mesenchymal cells [12-15].
CysLTs mediate their diverse effects through at least two
G-protein coupled receptors, CysLT1 and CysLT2. Both
receptors have been described in a variety of human cells,
including inflammatory cells like monocytes/macro-
phages, mast cells and eosinophils [16,17], expressed pre-
dominantly on the outer plasma membrane. Recently,
also an agonist-regulated localization of the CysLT1 in the
outer nuclear membrane was demonstrated in certain
cells [18,19].
Specific antagonists for CysLT1, such as montelukast and
zafirlukast, have been developed as active controller med-
icines for asthma [20], whereas a dual antagonist, BAY
u9773, is available for experimental use [21]. Apart from
reduction of airway subepithelial fibrosis by blockade of
the CysLT1 receptor with montelukast in a murine model
[22] and attenuation of airway myofibroblasts by monte-
lukast in human asthmatics following allergen challenge,
the knowledge about the effects of antileukotrienes on
remodeling of the airway ECM in humans is overall very
limited [11,15]. Since a failure in the injury-repair cycle of
the inflamed bronchial epithelium seems to play a major
role in the remodeling via development of abnormally
activated epithelial-mesenchymal interactions
[3,11,23,24], a study was undertaken on human bron-
chial epithelial cells to investigate whether CysLTs have a
direct effect on the synthesis of Tn and Ln β2 chain, pro-
teins thought both to reflect the activity of the ongoing
inflammatory remodeling and to affect airway compli-
ance in asthma. In this study, we also checked the differ-
ential expression of both CysLT receptors on these cells
and showed that although CysLT2 is significantly more
abundant in human bronchial epithelium, the enhanced
expression of the ECM proteins is mediated singly by
CysLT1.
Materials and methods
Cell culture
Normal human bronchial epithelial cells (line BEAS-2B)
were obtained from the American Type Culture Collection
(Manassas, VA, USA). The cells were cultured at 37°C in a
humidified atmosphere of 5% CO2 using serum-free epi-
thelial growth medium (BEGM; Cambrex, Walkersville,
MD, USA) supplemented with Bullet Kit (Cambrex) to
contain 0.5 ng/ml human recombinant epidermal growth
factor, 50 μg/ml bovine pituitary extract, 0.5 μg/ml hydro-
cortisone, 5 μg/ml insulin, 10 μg/ml transferrin, 0.5 μg/ml
epinephrine, 0.1 ng/ml retinoic acid, 6.5 ng/ml triio-
dothyronine, 50 μg/ml gentamicin and 50 ng/ml ampho-
tericin B. After reaching 50% subconfluency, the cells were
challenged with 0 to 100 nM concentrations of either
LTD4, the most potent or LTE4, the weakest though the
most stable of the CysLTs (both from Cayman Chemical,
Ann Arbor, MI, USA) during 24, 48, and 72 hours. TGF-β
1 (1 ng/ml) (Chemicon, Hampshire, UK), known to stim-
ulate Tn expression in BEAS-2B cells [8], served as a posi-
tive control. Montelukast sodium (1 μM, Merck-Frosst,
Pointe Clarie, Quebec, Canada) or BAY u9773 (1 μM,
Cayman Chemical) was added to the cell culture for 30
min before challenging with LTD4 or LTE4 to block the
CysLT effect mediated via CysLT1 or both CysLT receptors,
respectively. In settings, where LTD4-stimulation was
involved, parallel experiments were performed with the
presence of 5 mM L-cysteine (Sigma, St. Louis, MO, USA.)
in the media to inhibit catabolism of LTD4 into LTE4.
Antibodies
Mouse monoclonal antibody (clone 100EB2), which rec-
ognizes the fourth and fifth fibronectin-like repeats in Tn-
C [25] and reacts with two different Tn polypeptides, was
kindly donated by Prof. I. Virtanen (University of Hel-
sinki, Finland). Mouse monoclonal antibody (clone C4)
against  β2 chain of human Ln was obtained from the
Developmental Studies Hybridoma Bank (University of
Iowa, Iowa City, IA, USA). Rabbit polyclonal antibodies
against human CysLT1 and CysLT2 were from Cayman
Chemical. Horseradish peroxidase (HRP)-conjugated rab-
bit anti-mouse and swine anti-rabbit antibodies, fluores-
cein isothiocyanate (FITC)-conjugated rabbit anti-mouse
and swine anti-rabbit antibodies, as well as appropriate
mouse and rabbit isotype control antibodies to provide
negative controls were from Dako (Glostrup, Denmark).
Western blotting
Confluent cells were washed with cold PBS and lysed in
SDS sample buffer (62 mM Tris pH 6.8, 2% SDS, 0.1 M
dithiotreitol, 10% glycerol and 0.05% bromophenol
blue). Equal protein amounts (70 μg) were separated byRespiratory Research 2008, 9:44 http://respiratory-research.com/content/9/1/44
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6.5% or 8% SDS/polyacrylamide gel electrophoresis and
transferred onto polyvinylidene difluoride (PVDF) mem-
branes (0.45 μm, Micron Separations Inc., Westborough,
MA, USA), followed by blocking with 3% BSA in TBS/T
(10 mM Tris-HCl pH 7.5, 0.1 M NaCl and 0.05% Tween-
20) overnight at 4°C and probing for 1 h at room temper-
ature with primary antibody against Tn, Ln β2 chain,
CysLT1, or CysLT2 (1:50, 1:50, 1:250, and 1:250, respec-
tively). Expression of CysLT1 and CysLT2 were analyzed in
the presence or absence of appropriate specific receptor
blocking peptides (both from Cayman Chemical, at 1:1
ratio to the respective antibody) with two different
amounts of total BEAS-2B cell protein loaded (35 and 70
μg). After incubation, blots were washed twice for 10 min
with TBS/T, followed by incubation with the appropriate
HRP-conjugated secondary antibodies for 1 h at room
temperature. The immunoreactivity was visualized with
3,3'-diaminobenzidine tetrahydrochloride (Sigma, St.
Louis, MO, USA) reaction. To detect Tn and Ln β2 chain,
the respective culture media were analyzed analogously.
Flow cytometry
For flow cytometry studies, the BEAS-2B cells were washed
with PBS, fixed in 2% paraformaldehyde in PBS for 15
min at room temperature and permeabilized in PBS con-
taining 0.1% saponin. A total of 3.0 × 105 cells were resus-
pended in PBS supplemented with 3% BSA and 0.1%
saponin for 30 min. All subsequent steps were performed
in PBS containing saponin and BSA. The cells were incu-
bated with the primary antibody against Tn, Ln β2 chain,
CysLT1, or CysLT2 for 30 min, washed three times and
incubated with the appropriate FITC-conjugated second-
ary antibody for 30 min. After washing, cells were resus-
pended in PBS and single-color immunofluorescence
analysis of 15 000 cells was performed on a FACS Calibur
flow cytometer using CELLQuest software (Becton Dick-
inson, San Jose, CA, USA). Negative controls were pro-
vided by substituting the primary antibody with an
appropriate isotype control antibody.
Immunocytochemistry
Cells grown on coverslips were fixed with 4% paraformal-
dehyde in PBS for 15 minutes and permeabilized with
0.1% Triton X-100 in PBS for 10 minutes. The fixed cells
were blocked with 3% BSA in PBS prior to incubation for
1 h at room temperature with the primary antibodies
against Tn, Ln β2 chain, CysLT1, or CysLT2 (1:10, 1:10,
1:50, and 1:50, respectively). The coverslips were washed
three times with PBS and probed with appropriate HRP-
conjugated secondary antibodies. The brown immu-
noperoxidase reaction was developed with diaminobenzi-
dine, followed by hematoxylin counterstaining. The
coverslips were mounted face down on microscope slides
using a Permanent Mounting Media (Dako). The CysLT
receptors were alternatively immunofluorescence-stained
with FITC-conjugated swine anti-rabbit secondary anti-
body for 1 h at room temperature and mounted on slides
using a fluorescence mounting medium (Dako). The cells
were examined with an Olympus BX61 microscope
(Olympus Optical Co., Ltd., Tokyo, Japan) and images
were obtained using an Olympus DP70 digital camera
and DP70-BSW software (version 01.02.). Negative con-
trols were attained by substituting the primary antibody
with an appropriate isotype control antibody.
RNA isolation and RT-PCR
Total RNA was isolated from cultured BEAS-2B cells using
the guanidinium-thiocyanate-phenol-chloroform extrac-
tion method [26]. Total RNA concentration was deter-
mined on NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies, Inc., Wilmington, DE, USA)
and purity was checked by the A260/A280 ratio (ratios
between 1.9 and 2.1 were considered acceptable), in addi-
tion, an agarose gel was run to assess the quality. cDNA
was synthesized from 5 μg RNA with RevertAid™ H Minus
Moloney murine leukemia virus reverse transcriptase (Fer-
mentas, Vilnius, Lithuania) using oligo(dT)18  priming
according to manufacturer's instructions. The resulting
cDNA samples were amplified by polymerase chain reac-
tion (PCR) using a DNA thermal cycler (MJ Research,
Watertown, MA, USA) and the following specific oligonu-
cleotide primer pairs: for Tn, forward 5'-CAGCTC-
CACACTCCAGGTAC-3' and reverse 5'-
CTTTCGCTGGGCTCTGAAGG-3' giving a PCR product of
448 bp, for Ln β2 chain, forward 5'-GCTCGGCAGTT-
GGATGCTCTC-3' and reverse 5'-GCCCGCTCATTTTCCT-
CATAG-3' giving a PCR product of 315 bp, for CysLT1,
forward 5'-AGCCCCCACAAGACAATCAA-3' and reverse
5'-AGGAGAGGGTCAAAGCAACAA-3', providing a PCR
product size of 358 bp, for CysLT2, forward 5'-GCAAC-
CATCCATCTCCGTATC-3' and reverse 5'-CCAGGAAACG-
CACAACACTC-3', that gives a PCR product of 392 bp, and
for  β-actin, forward 5'-TCCCTGGAGAAGAGCTACGA-3'
and reverse 5'-ATCTGCTGGAAGGTGGACAG-3', giving a
PCR product of 362 bp. After an initial denaturation at
94°C for 3 min, PCR mixtures were amplified by 35 cycles
consisting of 94°C for 25 s, 58°C for 30 s, 72°C for 30 s
for Tn, by 30 cycles consisting of 94°C for 20 s, 57°C for
25 s, 72°C for 30 s for Ln β2 chain and 35 cycles consist-
ing of 94°C for 10 s, 60°C for 20 s and 72°C for 30 s for
the CysLT receptors, with a final extension at 72°C for 5
min. Amplified PCR products were separated by 2% agar-
ose gel electrophoresis, visualized by ethidium bromide
and photographed under ultraviolet transillumination
together with the 100 bp DNA ladder marker (Fermentas).
Omitting either the cDNA from the PCR reaction or
reverse transcriptase from the cDNA synthesis reaction
provided negative controls.Respiratory Research 2008, 9:44 http://respiratory-research.com/content/9/1/44
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Data analysis
The densitometric analysis of the Western blot and RT-
PCR results was performed with use of the Image Pro Plus
software (version 4.0, Media Cybernetics Inc., Silver
Spring, MD, USA) and the results are expressed as means
± SEM. For statistical analyses, the SPSS statistical package
(version 12.0) (Chicago, IL, USA) vas applied. Signifi-
cance was determined by Kruskal-Wallis test with subse-
quent post hoc analysis between stimulated and control
cells using Dunn's multiple comparison test. Two-tailed
Mann-Whitney rank sum test was applied for comparison
between data of two groups.
Results
Expression of tenascin
Immunoblot analysis of the non-stimulated control cells
demonstrated two bands of Tn-immunoreactivity repre-
senting polypeptides of Mr 280,000 and Mr 230,000 (Fig-
ures 1A, B, and 2B). Exposure of the cells to both LTD4 and
LTE4  for 48 h augmented the expression of the Tn
polypeptide doublet, as well as Tn mRNA in a concentra-
tion-dependent manner (Figures 1A, B, and 2A). No sig-
nificant time-dependence was seen, as analysis of the cells
stimulated for 24 and 72 h gave similar results (data not
shown). TGF-β1 also produced a significant increase in Tn
at both protein (Figure 2B) and mRNA level (Figure 2C).
No Tn was detectable in the culture media, regardless of
the treatment setting.
Immunocytochemically, Tn-specific reactivity localized
intracellularly in the BEAS-2B cells (Figure 1C) and, like
that detected with immunoblot, it increased in response
to both LTD4 and LTE4. Results from experiments combin-
ing 1 ng/ml TGF-beta and 10 nM LTD4 revealed an addi-
Effect of LTD4 and LTE4 on the expression of tenascin (Tn) protein in BEAS-2B human bronchial epithelial cells Figure 1
Effect of LTD4 and LTE4 on the expression of tenascin (Tn) protein in BEAS-2B human bronchial epithelial 
cells. A concentration-dependent increase in expression of Tn was detected by Western blot analysis in cell lysates after 
exposure of the cells to LTD4 (A) and to LTE4 (B) for 48 h. The data were quantified by densitometry and are expressed as fold 
increases above non-stimulated cells (mean ± SEM) (n = 12). C: Immunoperoxidase immunocytochemistry for Tn showing the 
basal expression of Tn and an increase by treatment with LTD4 and with LTE4. Images are reproduced from a single experi-
ment, but are representative findings of multiple staining experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. non-stimu-
lated cells.
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tive effect of both mediators on Tn expression. In
particular, the increase in Tn expression represented
approximately the sum of the effects achieved by both
mediators alone, assessed by both flow cytometry (Figure
2D) and RT-PCR analysis (Figure 2E). Presence of 5 mM
L-cysteine in the culture media did not affect the perform-
ance of LTD4 in relevant experimental series (Figures 2D
and 2E).
Expression of laminin β2 chain
Immunoblot analysis revealed an insignificant increase in
the expression of Ln β2 chain by the BEAS-2B cells from
Effect of LTD4, LTE4, and TGF-β1 on the expression of tenascin (Tn) in BEAS-2B human bronchial epithelial cells Figure 2
Effect of LTD4, LTE4, and TGF-β1 on the expression of tenascin (Tn) in BEAS-2B human bronchial epithelial 
cells. RT-PCR analysis detected increased expression of Tn mRNA in response to stimulation with LTD4 and LTE4 (A), TGF-β1 
(C), and LTD4 combined with TGF-β1 (E) for 48 h. B: Increased expression of Tn was detected by Western blot analysis in cell 
lysates after stimulation with TGF-β1 (B) for 48 h. The data were quantified by densitometry and are expressed as fold 
increases above non-stimulated cells (mean ± SEM) (n = 12). D: Augmented expression of Tn protein was detected by flow 
cytometry in response to LTD4 combined with TGF-β1, compared with the effect of LTD4 alone. Difference from isotype con-
trol mean fluorescence intensity (MFI) is presented (mean ± SEM). Presence of 5 mM L-cysteine in the culture media did not 
affect the expression levels of Tn (D, E). *p < 0.05, **p < 0.01, and ***p < 0.001 vs. non-stimulated cells. NS – non-significant.
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the basal level after stimulation with LTD4 and LTE4 for 48
h (data not shown). Immunocytochemistry showed a
faint intracellular staining following stimulation with
both CysLTs (Figure 3C). However, unlike that with Tn,
Western blot analysis of the culture media for Ln β2 chain
displayed already a detectable baseline level (Figures 3A
and 3B). Media from cultures treated with 10 and 100 nM
LTD4 (Figure 3A) but not with LTE4 (Figure 3B) showed a
significant increase in Ln β2 chain, but no time-depend-
ence was observed (data not shown). The expression of Ln
β2 chain mRNA was significantly up-regulated in BEAS-2B
cells by only 100 nM LTD4 (Figure 3D). TGF-β1 did not
affect the expression of Ln β2 chain at either protein (data
not shown) or mRNA (Figure 3E) level.
Expression of CysLT1 and CysLT2 mRNA and protein
For CysLT1, immunoreactive protein bands with molecu-
lar weights of approximately 66, 76, 88, 106, and 111 kDa
appeared on Western blots, whereas CysLT2 appeared as
55-, 62-, 117-, 122-, 131-, and a major 148-kDa band (Fig-
ure 4A). All these bands were blocked with the respective
blocking peptides. At lower protein load (35 μg), only a
148-kDa band for CysLT2 was visible. Immunocytochem-
istry also confirmed a positive reactivity for both CysLT1
and CysLT2 on BEAS-2B cells that consisted mainly of a
bright cytoplasmic staining in all visualized cells. The
staining pattern was similar for both receptors, however,
immunoreactivity for the CysLT2 was stronger (Figure 4C).
Flow cytometric analysis confirmed the presence of both
CysLT1 and CysLT2 on BEAS-2B bronchial epithelial cells,
as well as corroborated the more vigorous fluorescence for
CysLT2 compared to that for CysLT1 (Figure 4D).
RT-PCR analysis revealed the amplified fragments for
CysLT1 and CysLT2 that corresponded to the respective
expected sizes of the transcripts (Figure 4B). The signal
obtained for CysLT2, normalized to β-actin expression,
was somewhat higher than that for the CysLT1.
Effect of antileukotrienes on CysLT-induced up-regulation 
of ECM proteins
Both CysLT receptor antagonists montelukast and BAY
u9773 abolished the significant CysLT-induced increase
in Tn production at both protein (Figure 5A) and mRNA
level (Figure 5B). This inhibition was complete as the lev-
els of Tn expression after receptor blockade did not differ
from that in non-stimulated cells. Similarly, the signifi-
cant up-regulation of expression of Ln β2 chain mRNA by
100 nM LTD4 was fully prevented by both montelukast
and BAY u9773 (Figure 6). There was no statistical differ-
ence between the inhibitory effects of the CysLT1-specific
antagonist montelukast and the dual antagonist BAY
u9773 in any setting. In experiments, where LTD4 was
combined with 1 ng/ml TGF-β, both montelukast and
BAY u9773 reduced the expression of Tn protein and
mRNA down to the level not statistically differing from
that what was seen after stimulation with TGF-β alone
(Figures 5A and 5B). Neither of the antileukotrienes alone
significantly affected the baseline Tn and Ln β2 chain
expression. Neither montelukast nor BAY u9773 signifi-
cantly affected the TGF-β-induced Tn-expression (Figures
5A and 5B).
Discussion
In this study, we showed for the first time that CysLTs are
able to significantly augment the expression of Tn by
human bronchial epithelial cells. However, only LTD4 is
potent enough to enhance the expression of Ln β2 chain.
We also demonstrated that the CysLT-induced increase in
Tn and Ln β2 chain is mediated solely by the CysLT1 recep-
tor, as montelukast, a specific CysLT1  inhibitor, com-
pletely abolished this increase and dual inhibition of both
CysLT receptors did not provide any significant additional
effect.
It is remarkable that the CysLTs can produce increased
expression of Tn and Ln β2 chain even alone suggesting
that they act as independent remodeling-inducing media-
tors at least on human bronchial epithelial cells. This is
apart from that shown in a former study on human lung
fibroblasts in which LTD4 only augmented TGF-β-induced
collagen production, but had no effect alone [12]. One
could argue, however, for that the increased collagen lead-
ing to fibrosis on the one hand and Tn along with Ln β2
chain on the other may convey somewhat different signif-
icance with regard to tissue remodeling. Indeed, in con-
trast to collagens, Tn is an ECM protein, which shows
rapid tissue turnover represented by prompt increase fol-
lowed by a decrease either after discontinuation of the
adverse situation [10] or as a result of treatment [7]. How-
ever, increased Tn has been suggested to have dual signif-
icance within the airways. Beyond the role of acutely up-
regulated Tn in the inflammatory response and cell traf-
ficking, the deposition of Tn into the airway mucosa pro-
vides an addition to the increased accumulation of the
ECM components, such as collagens, leading to increased
airway narrowing and reduction in airway wall compli-
ance [10]. The accumulation of collagens and Tn share
even more common aspects. Tn is a matricellular protein
that facilitates both morphogenesis of epithelial organs
and re-epithelization after injury, but is also responsible
for correct rebuilding of the ECM, including proper depo-
sition of collagen [27]. This pertains with minor reserva-
tions also to the Ln β2 chain, which is transiently
expressed at the epithelial-mesenchymal border and
mediates morphogenetic events and organization of the
basement membrane (BM) up to the canalicular stage of
lung development [28]. In addition, increased expression
of both Tn [7] and Ln β2 chain [5] have been shown in the
subepithelial BM in patients with asthma in a manner parRespiratory Research 2008, 9:44 http://respiratory-research.com/content/9/1/44
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Effect of LTD4, LTE4 and TGF-β1 on the expression of laminin (Ln) β2 chain in BEAS-2B human bronchial epithelial cells Figure 3
Effect of LTD4, LTE4 and TGF-β1 on the expression of laminin (Ln) β2 chain in BEAS-2B human bronchial epi-
thelial cells. Western blot analysis revealed increased expression of Ln β2 chain in the cell culture medium in response to 
stimulation with LTD4 (A), but not with LTE4 (B) for 48 h. RT-PCR analysis detected increased expression of Ln β2 chain 
mRNA in response to 100 nM LTD4 (D), but no effect with either LTE4 (D) or TGF-β1 (E). The increase in response to LTD4 
was concentration-dependent. The data were quantified by densitometry and are expressed as fold increases above non-stim-
ulated cells (mean ± SEM) (n = 12). *p < 0.05 and ***p < 0.001 vs. non-stimulated cells. C: Immunoperoxidase immunocyto-
chemistry for Ln β2 chain showing no definite expression of Ln β2 chain by non-stimulated control cells with a slight increase 
after treatment with both LTD4 and LTE4. Images are reproduced from a single experiment, but are representative findings of 
multiple staining experiments.
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Analysis of cysteinyl leukotriene receptors CysLT1 and CysLT2 in BEAS-2B human bronchial epithelial cells Figure 4
Analysis of cysteinyl leukotriene receptors CysLT1 and CysLT2 in BEAS-2B human bronchial epithelial cells. A: 
Western blot analysis of CysLT1 and CysLT2 protein in the presence or absence of specific blocking peptide (BP) with increas-
ing amount of protein loaded. B: RT-PCR analysis of CysLT1 and CysLT2 mRNA. The graph represents densitometric results of 
CysLT1 and CysLT2, normalized to β-actin (mean ± SEM) (n = 9). *p < 0.05. C: Indirect FITC-immunofluorescence staining 
showing localization of cysteinyl leukotriene receptors in non-stimulated cells. D: Representative flow cytometric analysis of 
CysLT1 and CysLT2 on BEAS-2B cells. The open histograms correspond to cells labeled with isotype control antibody and the 
shaded ones represent cells labeled with the respective anti-CysLT antibodies.
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Inhibition by antileukotrienes of tenascin (Tn) expression in cysteinyl leukotriene-stimulated BEAS-2B human bronchial epithe- lial cells Figure 5
Inhibition by antileukotrienes of tenascin (Tn) expression in cysteinyl leukotriene-stimulated BEAS-2B human 
bronchial epithelial cells. A: Flow cytometric analysis showed full inhibition by both montelukast (MLK) and BAY u9773 of 
LTD4- or LTE4-induced increase in Tn protein expression to the levels not differing from that in non-stimulated cells. Differ-
ence from isotype control mean fluorescence intensity (MFI) is presented. B: RT-PCR analysis of Tn mRNA showing inhibition 
of the cysteinyl leukotriene-induced up-regulation by both MLK and BAY u9773. Partial inhibition of Tn expression induced by 
combined LTD4 and TGF-β1 down to the level not differing from that what was seen after stimulation with TGF-β1 alone was 
shown at both protein (A) and mRNA (B) level. There was no statistical difference between the inhibitory effects of MLK and 
BAY u9773 in any setting. Data are expressed as mean ± SEM (n = 12) *p < 0.05, **p < 0.01, and ***p < 0.001. NS – non-signif-
icant.
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alleling the severity and duration of the disease. Not only
this refers to the involvement of these proteins in the
remodeling of the ECM, but suggests also a reverse quan-
titative expression pattern, compared to that observed
during the human fetal airway morphogenesis. In this
light, the increased synthesis of Tn and Ln β2 chain by
bronchial epithelial cells in response to CysLTs in the
present study may be reminiscent of an inflammatory
response in which CysLT-rich milieu is a characteristic fea-
ture, like this is the case in asthma [29]. It has been sug-
gested that inflammatory mediator-induced submucosal
remodeling is initiated through the bronchial epithelium
[30]. According to this widely accepted model, the stimu-
lated or injured epithelial cells drive the mesenchymal
cells within the epithelial-mesenchymal trophic unit in a
way similar to the processes during the fetal development
[3]. Our present findings supplement this knowledge with
the ability of the bronchial epithelial cells to contribute to
the airway remodeling even independently on the com-
munication with mesenchymal cells.
To strengthen the evidence that CysLTs act directly on the
human bronchial epithelial cells that results in increased
Tn and Ln β2 chain synthesis, we next focused on the
expression of the two CysLT receptors on these cells. Of
the overall human respiratory epithelium, the presence of
CysLT1 and CysLT2 have been formerly described immu-
nohistochemically on nasal mucosal epithelium in both
healthy individuals and patients with chronic rhinosi-
nusitis [31]. Both CysLT receptors have been described
also in the epithelium of palatine tonsils of pediatric
patients with sleep apnea and recurrent throat infections
[32]. Recently, with use of immunohistochemistry and in
situ  hybridization, a weak and moderate expression of
CysLT1 has been described in bronchial epithelial cells of
controls and asthmatics, respectively [33]. Interestingly,
only some but not all bronchial epithelial cells appeared
to show expression of the CysLT1 protein in that particular
study and unfortunately, expression of CysLT2 was not
addressed. Thus, the expression of both CysLT receptors
on BEAS-2B human bronchial epithelial cells at both
mRNA and protein level in the present study is partly in
line with and partly supplement the data obtained by pre-
vious investigators. The evidence we have obtained that
the CysLT2 is more abundant on human bronchial epithe-
lial cells than the CysLT1 is supported by the results of an
immunohistochemical study of Corrigan and co-authors
on nasal epithelial cells [31]. RT-PCR analyses in our
present study did support our immunofluorescence and
flow cytometry findings strengthening the possibility that
the stronger immunoreactivity for CysLT2 reflects the true
higher expression of CysLT2 compared to that of CysCT1
rather than results from different antibody performances.
Our Western blot analysis of the CysLT1 displayed several
protein bands, which obviously correspond to the oligo-
meric forms (Figure 4A). This is in agreement with previ-
ous reports, which along with the monomeric form have
demonstrated larger amounts of dimerized and oligomer-
ized CysLT1 even in the presence of denaturing gel deter-
gents [34]. When probing for CysLT2, also several specific
immunoreactive bands were detected with a major band
at approximately 148 kDa, corresponding most likely to
the oligomers of the receptor. Although the evidence that
the CysLT receptor immunoreactivity was completely
blocked by the blocking peptides supports the specificity
of the detected bands, the molecular weights do not pre-
cisely correspond to monomers and homo-oligomers of
the CysLT receptors. This could be explained by post-
translational modifications, but rather by the possibility
of composing heterodimers and hetero-oligomers, which
is a characteristic feature of G-protein-coupled receptors
[35].
The CysLT-induced increase in Tn and Ln β2 chain pro-
duction by bronchial epithelial cells was completely abol-
ished by both CysLT1-specific antagonist montelukast and
a dual antagonist for both CysLT1 and CysLT2 receptors,
BAY u9773. Furthermore, increased Tn expression as a
result of combined stimulation with LTD4 and 1 ng/ml
TGF-β was reduced by both montelukast and BAY u9773
down to the levels not statistically differing from that
what was seen after stimulation with TGF-β alone. This
may refer to the possibility that CysLTs may affect Tn
Inhibition by antileukotrienes of laminin (Ln) β2 chain expres- sion in cysteinyl leukotriene-stimulated BEAS-2B human  bronchial epithelial cells Figure 6
Inhibition by antileukotrienes of laminin (Ln) β2 
chain expression in cysteinyl leukotriene-stimulated 
BEAS-2B human bronchial epithelial cells. RT-PCR 
analysis of Ln β2 chain mRNA showing significant inhibition 
of the 100 nM LTD4-induced up-regulation by both montelu-
kast (MLK) and BAY u9773. There was no statistical differ-
ence between the inhibitory effects of MLK and BAY u9773. 
Data are expressed as mean ± SEM (n = 12) *p < 0.05, **p < 
0.01, and ***p < 0.001.
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expression independently of TGF-β. Since montelukast
appeared to be sufficient to block the effect of the CysLTs
and there was no difference between the two antileukot-
rienes for their inhibition activities, the results allow us to
suggest that the CysLT-induced increase in Tn and Ln β2
chain in bronchial epithelial cells is mediated through the
CysLT1 receptor.
Conclusion
Our present results demonstrate for the first time that the
CysLTs LTD4 and LTE4 augment production of Tn, whereas
LTD4 enhances also synthesis of Ln β2 chain by human
bronchial epithelial cells and this effect is mediated via
the CysLT1 receptor. The results not only point to the pos-
sibility that, when exposed to CysLTs, the epithelial cells
can participate in the development of airway remodeling
independently on communication within the epithelial-
mesenchymal trophic unit, but also implies that treat-
ment with CysLT1 receptor antagonists can be effective to
suppress this important mechanism of airway remodeling
in asthma.
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